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Pathological erythropoiesis with consequent anemia is a leadingcause of symptomatic morbidity in internal medicine. The etiologiesof anemia are complex and include reactive as well as neoplastic
conditions. Clonal expansion of erythroid cells in the bone marrow may
result in peripheral erythrocytosis and polycythemia but can also result in
anemia when clonal cells are dysplastic and have a maturation arrest that
leads to apoptosis and hinders migration, a constellation typically seen in
the myelodysplastic syndromes. Rarely, clonal expansion of immature
erythroid blasts results in a clinical picture resembling erythroid
leukemia. Although several mechanisms underlying normal and abnor-
mal erythropoiesis and the pathogenesis of related disorders have been
deciphered in recent years, little is known about specific markers and tar-
gets through which prognosis and therapy could be improved in anemic
or polycythemic patients. In order to discuss new markers, targets and
novel therapeutic approaches in erythroid disorders and the related
pathologies, a workshop was organized in Vienna in April 2017. The out-
comes of this workshop are summarized in this review, which includes
a discussion of new diagnostic and prognostic markers, the updated
WHO classification, and an overview of new drugs used to stimulate or
to interfere with erythropoiesis in various neoplastic and reactive condi-
tions. The use and usefulness of established and novel erythropoiesis-
stimulating agents for various indications, including myelodysplastic syn-
dromes and other neoplasms, are also discussed. 
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ABSTRACT
Introduction
Erythropoiesis is one of the important physiological
supply functions of the bone marrow. In healthy adults,
about 200x109 red cells are produced per day in the bone
marrow and are released into the peripheral blood.1
Depending on demand, red cell production can be adjust-
ed and upregulated substantially. A complex network of
oxygen sensors, cytokines, such as erythropoietin, and
other factors, including regulators of iron metabolism, are
involved in the control of steady-state and stress-induced
erythropoiesis, thereby ensuring appropriate oxygen sup-
ply to the peripheral tissues.2-5 This regulatory network
can adjust itself to physiological requirements such as the
oxygen concentration (altitude) or pregnancy as well as to
pathological conditions such as blood loss.2-5 However, in
some pathological conditions this regulatory network is
overwhelmed or is not functional, resulting in poly-
cythemia or anemia. 
In the elderly, the bone marrow and other organs under-
go aging. As a result, erythropoietin synthesis and red cell
production may decline.6-9 However, even in very old indi-
viduals, red cell production and erythropoietin synthesis
are usually adequate to keep hemoglobin levels within a
reasonable range unless certain co-morbidities that lead to
insufficient production of red cells have been acquired.6-9
Therefore, such other etiologies must be ruled out when
hemoglobin levels drop in older individuals.7-9
Anemia is a major cause of symptomatic morbidity in
daily medical practice. The etiologies contributing to ane-
mic states are complex.6-14 Underlying disorders include
trauma or coagulopathies with consequent bleeding,
immunological and other inflammatory reactions as well
as clonal (neoplastic) conditions. Clonal expansion of ery-
throid progenitor cells in the bone marrow may result in
central and peripheral expansion of erythropoiesis, and
thus in the clinical picture of polycythemia vera (PV), but
it may also result in clonal anemic states such as the
myelodysplastic syndromes (MDS) or even erythroid
leukemia, characterized by a major or complete block of
differentiation in early erythropoiesis.15-18 Anemic MDS
are characterized by red cell dysplasia, ineffective erythro-
poiesis, apoptosis of late erythroid precursor cells, and the
paradoxical combination of erythroid bone marrow
hyperplasia and peripheral anemia.    
Although several mechanisms underlying normal and
pathological red cell production in the bone marrow have
been identified in recent years, little is known about dis-
ease-related markers and targets through which prognos-
tication and therapy may be improved in anemic or poly-
cythemic patients. In order to discuss novel markers, tar-
gets and mechanisms as well as new therapeutic
approaches and strategies in various erythroid disorders, a
workshop was organized in Vienna in April 2017 (April
28-29). The discussion in this meeting focused on patho-
logical (neoplastic) erythropoiesis in adults. The outcomes
of this workshop are summarized in this review.
Erythropoiesis
Molecular mechanisms controlling erythropoiesis 
in health and disease
A network of interconnected physiological communica-
tion networks and pathways are responsible for the pro-
duction, distribution and turnover of red blood cells in
healthy individuals (Figure 1).2-5,19-26 These networks keep
the hemoglobin concentrations at a remarkably stable
level throughout lifetime. Erythropoiesis starts in the bone
marrow with lineage commitment of pluripotent myeloid
progenitor cells and differentiation of these cells into
immature erythroid progenitors that retain a certain pro-
liferative capacity. Subsequently, these progenitor cells
undergo further differentiation and maturation. A com-
plex network of transcription factors and epigenetic regu-
lators orchestrates this process.22-31 GATA-1 is the main
regulator of lineage commitment, differentiation and sur-
vival of erythroid progenitors (Figure 1).20,22,27-30 In particu-
lar, GATA-1 triggers erythropoiesis by regulating the tran-
scription of several erythroid differentiation-related genes,
including genes involved in heme and/or globin synthesis,
glycophorins, anti-apoptotic genes of the BH-3 family,
genes involved in cell cycle regulation, and the gene for
the erythropoietin receptor (EPOR).20,22,28 Major molecular
players in these networks include, among others, classical
hormones (thyroid hormones, androgens, corticosteroids,
activin/inhibin and others), vitamins (e.g. vitamin B12 and
folic acid), iron, regulators of iron metabolism such as the
transferrin receptors-1 and -2, and early acting hematopoi-
etic growth factors such as stem cell factor and inter-
leukin-3 (Figure 1A).20-33
The main cytokine regulator of red cell production is
erythropoietin, which acts at the level of late erythroid
progenitors through a homodimeric receptor that triggers
JAK2 kinase activity and subsequently STAT5 activation
(Online Supplementary Figure S1). Erythropoietin acts main-
ly on myeloid precursor cells to ensure survival, thereby
allowing the erythroid differentiation program, induced
mainly by GATA-1, to occur (Figure 1A).2-5 It has been sug-
gested that erythroid precursors in the bone marrow
exhibit differential sensitivity against erythropoietin. The
less sensitive cells undergo apoptosis upon caspase activa-
tion when the erythropoietin level is low, whereas at
higher erythropoietin levels, most cells will survive and
differentiate (Figure 1). In addition, in the bone marrow,
within erythroid blood islands, late erythroid precursor
cells express FAS ligand which may interact with early
erythroid precursors that express FAS, resulting in caspase
activation, which in turn triggers apoptosis and matura-
tion arrest (Figure 1). In the case of a substantial need to
produce more erythroid cells (e.g. after blood loss by
bleeding or hemolysis), erythropoietin counteracts this
activation allowing the cells to survive and differentiate,
even if late erythroid precursors are abundant. In erythro-
poiesis, caspases, upon activation, cleave not only their
main natural targets in the nucleus, but also GATA-1,
which amplifies cell death and blocks erythroid differenti-
ation (Figure 1).30 Erythropoietin synthesis is regulated in
peritubular cells of the kidney by the transcription factor
hypoxia-inducible factor-α, the main regulator of tran-
scription of the gene encoding for erythropoietin (EPO).
The stability of hypoxia-inducible factor-α depends on the
prolyl-hydroxylase enzyme and the concentration of oxy-
gen.32 To ensure a high level of proliferation and hemoglo-
bin synthesis, iron absorption and the availability of iron
for erythroid cells are tightly regulated by a number of
modulators of iron metabolism and iron uptake. The latter
include transferrin and its receptors (TfR-1 and TfR-2), as
well as hepcidin and its target ferroportin, which allow
iron export from various cell types, including
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macrophages and enterocytes, and thereby make iron
available to erythroid progenitor cells.33 Erythroferone,
which is synthesized by early and late erythroid progeni-
tor cells, has recently been described as a major regulator
of hepcidin synthesis in the liver.34 In addition to its role in
iron uptake, transferrin receptor-1 is also able to trigger the
MAP kinase and phosphoinositide 3 kinase/AKT path-
ways induced by erythropoietin and may thus participate
in the regulation of erythropoiesis.35
In the model of regulation of red cell production by the
modulation of erythropoietin sensitivity and rate of apop-
tosis of erythroid progenitor and precursor cells, caspases
are considered to be key enzymes (Figure 1).27-31 To add to
the complexity of the system, it has been shown that cas-
pases are also activated during erythroid differentiation
and that this activation is absolutely necessary to prepare
the cells for enucleation and thus formation of mature red
cells (Figure 1C,D). In this process, GATA-1 is not cleaved
by caspases, ensuring that erythroid maturation is pre-
served. To explain this apparent paradox it has been
shown that the chaperone heat shock protein 70 (HSP70)
plays an essential role in protecting GATA-1 from caspase
cleavage (Figure 1C,D).25-31 Indeed, during erythroid differ-
entiation HSP70 enters the nucleus at the time of caspase
activation, and, at this level, interacts with GATA-1 to pro-
tect it against cleavage. By contrast, during apoptosis
Normal and pathological erythropoiesis
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Figure 1. Major pathways and molecules involved in the regulation of erythropoiesis. (A) Development of erythropoietic progenitor cells and erythroblasts. Early
stages of erythropoietic development include primitive (p) and more mature (m) burst-forming unit erythroid cells (BFU-E) and colony-forming unit erythroid cells (CFU-
E). The differentiation and maturation of these cells are regulated by broadly acting hematopoietic cytokines, including stem cell factor (SCF) and interleukin-3 (IL-3)
and their receptors (R), the SCF receptor KIT and IL-3-R. Later stages are primarily regulated by erythropoietin (EPO) and EPO-R and are dependent on iron-metabolism
and the interaction between the death receptor FAS and its ligand (FAS-L). Transferrin (Tf) and Tf-receptor-1 (TfR-1) are additional major regulators of erythropoiesis.
Moreover, growth differentiating factor 11 (GDF11) and polymeric immunoglobulin A (IgA) are considered to be involved in the regulation of certain stages of erythro-
poiesis. Later stages of erythropoiesis include proerythroblasts (ProEbl), basophilic (Baso) erythroblasts (type I and II), polychromatic (PolyC) erythroblasts and aci-
dophilic (Acido) erythroblasts, also called late erythroblasts (Barbara Bain, personal communication to MCB). FAS-L and GDF11 are involved in the final maturation
stage that leads to the generation of red cells (RC). (B) Erythroid blood island: macrophage surrounded by immature erythroblasts expressing FAS and more mature
erythroblasts expressing FAS-L. The cell unit (island) acts in concert to promote erythroid differentiation and red cell production and maturation (rectangle). (C)
Caspase activation during terminal erythroid differentiation: BID-dependent activation of caspase occurs in mitochondria. Various caspase targets are affected, includ-
ing Rock-1, Lamin B and Acinus. However, GATA-1 is protected from caspase cleavage by heat shock protein 70 (HSP70). (D) Model of terminal erythroid differentiation
and apoptosis regulated by the nuclear localization of HSP70. SCF and EPO trigger the proliferation and differentiation of erythroid progenitor cells (EPC). In RC pre-
cursors (CFU-E through erythroblasts) EPO induces maturation as HSP70 translocates into the nucleus to protect GATA-1 from caspase-induced degradation. In the
absence of EPO, caspase-3 induces the cleavage of GATA-1 as HSP70 cannot translocate to the nucleus, and, as a result, apoptosis occurs.   
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induced by erythropoietin deprivation, HSP70 is exported
from the nucleus and allows GATA-1 cleavage in ery-
throid progenitor cells (Figure 1D).25-31 This model, in
which the fate of erythroid precursors is determined by
the localization of HSP70 in the nucleus, has been shown
to be altered in ineffective erythropoiesis in various ane-
mic conditions such as b-thalassemia, MDS,36 and congen-
ital erythroblastopenia,37 and may provide a new concep-
tual basis to improve anemia in these diseases.31
Apart from these established regulators of erythro-
poiesis, several novel molecular players regulating ery-
thropoiesis were discussed in the workshop. Among these
are members of the BCL-2 family such as BID which may
play a critical role in the regulation of mitochondrial depo-
larization and caspase activation during erythroid differ-
entiation and apoptosis (Figure 1C), various transcription
factors, including STAT5A and STAT5B (Table 1),
cytokines such as growth differentiating factor 11
(GDF11), and regulators of iron uptake and iron metabo-
lism.33-48 GDF11, a ligand of activin receptor IIA (ActRIIA)
that accumulates in erythroblasts in patients with b-tha-
lassemia, has been implicated in the pathogenesis of ane-
mia in these patients.42
It has also been described that polymeric immunoglob-
ulin A (IgA) produced in the bone marrow may bind to the
transferrin receptor-1 to sensitize erythroid cells to ery-
thropoietin (Figure 1A).35 Consistent with this role as a
regulator of erythropoiesis, the synthesis of polymeric IgA
is increased during hypoxia. In pathological conditions,
patients with IgA deficiency have higher levels of erythro-
poietin and, conversely, patients with unexplained poly-
cythemia associated with an excess of polymeric IgA syn-
thesis have recently been reported.35 Finally, a number of
regulators of red cell membrane stability have recently
been identified. One of these regulators may be CDK6, a
cell cycle regulator that has recently been shown to serve
as a membrane stabilizer of red cells in mice.49
Diagnostic evaluation of erythropoiesis: established
and novel markers 
In most anemic patients the underlying etiology can be
identified rapidly through the information gained from a
thorough case history and detailed laboratory investiga-
tions. A number of different etiologies can underlie ane-
mia, including iron deficiency, chronic inflammation,
hemolysis, renal disorders or vitamin B12 deficiency. In
each case, it is important to follow the principle diagnostic
algorithms, to establish the correct diagnosis and to treat
the underlying disorder (for example a gastrointestinal dis-
ease). In most of these cases, investigation of the bone
marrow is not required. In other patients, however, the
etiology remains uncertain after initial studies, so that
detailed investigations of the bone marrow have to be per-
formed. These investigations include a thorough cytologi-
cal, histological and immuno-histochemical examination
of the bone marrow, multi-parameter flow cytometry
studies, a detailed examination of chromosomes
(metaphases by conventional karyotyping and interphases
by fluorescence in situ hybridization) and molecular stud-
ies.9-11,50-52 Depending on blood counts and other parame-
ters, fluorescence in situ hybridization studies are applied
to screen for the presence of MDS-related abnormalities.
Our faculty recommends that in each case morphological
and immunophenotypic studies, including immunohisto-
chemistry and flow cytometry, should be employed to
define the percentage and stage of maturation of erythroid
cells in bone marrow samples.52
For routine diagnostics, recommended immunohisto-
chemical markers are glycophorin A, CD71 and E-cad-
herin (Table 2). Additional immunohistochemical markers
include glycophorin C and hemoglobin A. E-cadherin is of
special value for the detection of immature erythropoietic
progenitor cells in patients with MDS and those with ery-
throleukemia (Figure 2). In contrast, hemoglobin A is pref-
erentially expressed in more mature erythroblasts, and
may therefore be helpful in distinguishing between more
mature and more immature cells.
In flow cytometry studies, recommended markers are
P. Valent et al.
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Table 1. Selected regulators of erythropoiesis.
Type of Regulator                            Major Examples
Growth factors for multipotent          SCF, G-CSF, IL-3
and early erythropoietic 
progenitor cells
Later-acting erythropoietic                 EPO, TGF-beta, GDF11,
differentiation factors                          Activin A
Essential transcription factors          GATA-1, STAT5A, STAT5B
Important survival factors for             MCL-1, BCL-xL, HSP70*
erythropoietic cells
Negative growth regulators of            Inhibin, TGF-beta, BID,
erythropoietic progenitor cells          FAS ligand, FAS, Caspases*
Essential vitamins and                          Vitamin B12, Folic acid,
trace elements                                       Copper, others
Iron and proteins involved                  Ferritin, Transferrin, 
in iron distribution and                        Transferrin receptor (CD71) 
iron metabolism                                     Ferroportin, Hepcidin
SCF: stem cell factor; G-CSF: granulocyte colony-stimulating factor; EPO: erythropoietin; TGF-
beta: transforming growth factor beta; GDF11: growth differentiation factor 11, also known as
bone morphogenetic protein 11; HSP70: heat shock protein 70. *HSP70 prevents caspase-
induced cleavage of GATA1 in erythropoietic progenitor/precursor cells.
Table 2. Markers used to identify and quantify erythropoietic cells in the bone
marrow.
                                                                                                       Specificity for
Marker                                        Ery-PC                     Ery           erythropoietic cells 
Flow cytometry                                  
CD36/ GP4                                             ++                              +                                 -
CD235a / Glycophorin A                     ++                          +++                           ++
CD71 / TfR-1                                          ++                            ++                               -
E-Cadherin                                            ++                              +                               +*
CD105 / endoglin                                 ++                            +/-                                -
Immunohistochemistry
CD235a / Glycophorin A                     ++                          +++                           ++
CD236 / Glycophorin C**                  ++                            ++                             ++
Hemoglobin A                                       +/-                            ++                             ++
CD71 / TfR-1                                          ++                            ++                             +/-
E-Cadherin*                                         ++                              +                               +*
CD105 / endoglin                                 ++                            +/-                                -
*Within the hematopoietic  cell system, expression of E-cadherin is rather specific for red cells
and their progenitors. **In immature erythroid leukemia, blast cells may stain negative for gly-
cophorin A, but are still positive for glycophorin C and E-cadherin. Ery-PC: erythroid progenitor
cells; Ery: erythrocytes; GP4: platelet plycoprotein-4; TfR-1: transferrin receptor-1.
glycophorin A, CD71, and CD105 (Table 2).53-56 Among
these, CD105 is of special value for the detection of imma-
ture erythropoietic progenitors in the bone marrow of
patients with MDS. E-cadherin is also expressed specifi-
cally on the surface of erythropoietic progenitor cells in
human bone marrow.57 However, E-cadherin is not used
routinely as an erythroid marker in flow cytometry stud-
ies. Our faculty is of the opinion that CD105 and E-cad-
herin should be validated further as routine diagnostic
markers in erythroid disorders of the bone marrow.
Another interesting aspect is that several cell surface anti-
gens appear to be downregulated on erythroid progenitor
cells in MDS patients.58 Among these antigens, the cox-
sackie-adenovirus receptor (CAR) is a rather specific anti-
gen: in fact, a decrease or lack of this receptor on erythroid
progenitor cells is typically seen in patients with MDS and
in other bone marrow neoplasms accompanied by marked
dysplasia.58 Immunophenotypic studies are also of great
importance to identify immature stages of erythropoiesis
in patients with acute (myeloid/erythroid) leukemia in
whom morphological and molecular studies alone are
insufficient to establish a correct diagnosis (Figure 2 and
Online Supplementary Figure S2). In these cases the use of
immunohistochemical studies and multiparameter flow
cytometry is essential.
Another important aspect is that the physiological
development and maturation of red cells in the bone mar-
row is regulated by the supporting microenvironment
(consisting of macrophages and stromal cells) in so-called
erythroid islands.59 These islands, also known as erythro -
blastic islands, are considered to represent functional units
and are detectable by conventional stains and specific
immunological stains (see above) on bone marrow biop-
sies. With age, the number of erythroid islands in the bone
marrow decreases, while their size increases, which may
suggest that the decrease in stem cell numbers and ery-
throid progenitors during aging might be compensated by
an increased proliferation of local erythroid progenitors
(Figure 3).60 In patients with MDS, impaired formation of
erythroid islands as well as structural abnormalities within
these islands have also been described (Figure 3).60 In low-
risk MDS, abnormal formation of erythroid islands may
be the only histopathological change found in the bone
marrow. Moreover, it has been described that erythroid
island density correlates inversely with overall survival in
patients with MDS.60 However, alterations of island con-
figuration and size (e.g. increased size) can also be detect-
ed when an increase in red cell production is required in
pathological conditions, such as in hemolytic anemia or
acute blood loss. In patients with aplastic anemia and
other bone marrow failure syndromes, only a few or no
erythroid islands are found in pathological examinations,
which we consider to be relevant diagnostically.
There are a number of established peripheral parameters
through which red cell production can be assessed quanti-
tatively. The most widely applied approach is to measure
the numbers of reticulocytes in the peripheral blood.
Another approach is to quantify the numbers of circulating
erythroid progenitor cells, including multi-lineage colony-
forming progenitors (CFU-GEMM) and burst-forming
units (BFU-E). With this approach, clonal cytopenias
(MDS) and aplastic anemia (in both conditions, CFU-
GEMM and BFU-E are markedly reduced or absent) are
separable from ‘reactive’ and ‘deficiency’ anemias in which
BFU-E and CFU-GEMM are usually within normal
ranges.61-63 Even in MDS patients with 5q-, who may devel-
op thrombocytosis, erythropoiesis and BFU-E growth are
usually suppressed. Factor (erythropoietin)-independent
and erythropoietin-hyperresponsive growth of BFU-E is
indicative of (almost diagnostic for) the presence of PV or a
related myeloproliferative neoplasm (MPN).64,65 However,
the colony-assay is rather tricky and its success depends on
the experience of the team performing the test. Thus,
although this assay is of practical value (and was previous-
ly used as a criterion for PV), it is nowadays only employed
routinely in a few specialized centers.
Anemia
Classification of anemia: novel aspects and etiologies
In general, anemia can be classified based on the regen-
erative capacity of the bone marrow (hypo- or hyper-
regenerative), the red cell volume (micro-, normo- or
macrocytic), the etiology (bleeding, deficiency-induced,
hemolytic, renal, inflammation-related, neoplastic, aplas-
tic, others) and the dynamics with which anemia develops
(acute, chronic).9-11 For each specific form of anemia, an
extensive amount of published data has accumulated dur-
ing the past few decades. A detailed description is beyond
the scope of this article. There are also special variants of
anemia that develop typically in the context of certain
Normal and pathological erythropoiesis
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Figure 2. Immunophenotypic visualization of leukemic erythroblasts. Bone marrow sections of a patient with erythroid leukemia (acute erythroleukemia) stained
with (A) Wright-Giemsa solution and antibodies against (B) glycophorin A and (C) E-cadherin. Note that virtually all leukemic erythroblasts co-express abundant
amounts of glycophorin A and E-cadherin, thereby confirming the immature stage of maturation of leukemic (erythroid) cells. 
physiological conditions such as pregnancy or advanced
age.8,9,66,67 In these cases, the primary question is whether
anemia is indicative of an undetected pathology and
whether and when (at what thresholds) anemia can
indeed be diagnosed. For example, in pregnant women, a
hemoglobin level of 11.0 g/dL is still considered to be
within the normal range by the World Health
Organization (WHO). In elderly individuals, however, any
decrease of hemoglobin below ‘normal’ is considered an
anemia.8,9 On the other hand, there is an ongoing discus-
sion about the definition of anemia in the elderly and
related hemoglobin thresholds.9,68-70 When no evidence of
an underlying condition is found after a thorough investi-
gation of all relevant organs and potential etiologies, the
condition is termed cytopenia (anemia) of unknown sig-
nificance (ICUS-A).50,52 Thus, the diagnosis of ICUS-A
implies that a detailed investigation of the bone marrow,
with histological, morphological (cytological),
immunophenotypic, cytogenetic and molecular studies,
was performed without conclusive evidence of the pres-
ence of MDS or any other underlying bone marrow neo-
plasm.50,52 In this regard it is worth noting that next-gener-
ation sequencing may sometimes reveal more or less spe-
cific mutations which may lead to re-classification of
ICUS-A cases into either clonal cytopenia of undeter-
mined significance or low-risk MDS, respectively.50-52
Other differential diagnoses to ICUS-A include anemia of
chronic disease (inflammation-associated anemia),
hemodilution, renal anemia, copper deficiency and vita-
min B12 deficiency.9-11 In some elderly patients with ICUS-
A, inadequately low levels of erythropoietin are found
even though the excretory function of the kidney is nor-
mal.71,72 In such cases, the aged kidney may be responsible
for low erythropoietin production. Another equally
important contributor to low red cell and erythropoietin
production in elderly (otherwise healthy) people may be
an age-related decrease in the production of hypophyseal
and other essential hormones, resulting in a decreased
supply of testosterone.73 However, unless an additional
pathology (co-morbidity) is also present, these individuals
have only mild anemia and are free of symptoms. As men-
tioned, it remains uncertain as to whether all these elderly
individuals should indeed be diagnosed as having overt
anemia.
P. Valent et al.
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Figure 3. Structure and size of erythroid
islands in the bone marrow. (A) Erythroid
islands in the bone marrow of a 16-year old
healthy male visualized by staining for
CD71. (B) Erythroid islands in the bone
marrow of an 82-year old female without
bone marrow neoplasm. Erythroid islands
were visualized by staining against hemo-
globin A. Note the decreased number and
increased size of erythroid islands in the
bone marrow of the older healthy control.
(C) Erythroid islands in the bone marrow of
a 73-year old male patient with myelodys-
plastic syndrome with excess of blasts (5-
9% of marrow cells, MDS-EB-1) visualized
by staining for CD71. In the right images of
3A, 3B and 3C, erythroid islands are evi-
denced by pink circles. Note the decreased
number of erythroid islands in this patient.
(D, left panel) Bone marrow section of a
78-year old male with myelodysplastic syn-
drome with excess of blasts (10-19% of
marrow cells, MDS-EB-2) stained for CD71.
In this patient, numerous confluent, par-
tially disrupted and poorly separable ery-
throblastic islands are seen. (D, right
panel) Bone marrow section of an adult
patient with hemolytic anemia. Note that
erythroid islands are increased, but are
clearly separable and have a regular shape
(contrasting with MDS). Original magnifica-
tions: A, C, D: x 125; B: x 250.
Refractory anemias: the updated World Health
Organization classification and novel molecular 
markers and targets used to grade and classify 
the disease 
In the current WHO proposal (2017) the term refractory
anemia has been removed and replaced by the term MDS
with an additional explanatory appendix to define the
number of lineage(s) involved with dysplasia (example:
MDS with single lineage dysplasia).74-76 It is important to
note that MDS with single lineage dysplasia can be sepa-
rated into anemic, neutropenic and thrombocytopenic
types. Table 3 shows the current WHO proposal to clas-
sify MDS. Another important aspect is that only a few
cytogenetic and molecular markers are used to define the
subtype of MDS. For example, the 5q- syndrome is recog-
nized as a separate entity by the WHO (MDS with isolat-
ed 5q-) and is associated with particular sensitivity to
lenalidomide. It has also been described that the SF3B1
mutation is highly indicative of the presence of ring
sidero blasts.74-76 Therefore, this mutation, when present,
serves as a diagnostic feature. In particular, MDS variants
with ring sideroblasts can be diagnosed when ring sider-
oblasts account for either ≥15% of all red cells (old defi-
nition) or ≥5% in the presence of a SF3B1 mutation (new
adjunct).74-76 For the morphologist, this definition implies
that more red cells have to be counted in the iron stain (at
least 100 red cells) to arrive at a correct diagnosis.52 This
individualization might be of importance because
patients with this disorder usually do not respond to ery-
thropoietin but may benefit from specific treatment, such
as a GDF11 inhibitor. Another relevant change in the cur-
rent WHO classification (update 2017) relates to the defi-
nition of erythroleukemia. Details are discussed below
under the section ‘Red cell neoplasms’. Based on the
changed definition, a new subset of poor-risk patients
with MDS, formerly diagnosed as having erythroid
leukemia or M6 acute myeloid leukemia (AML) according
to the French-American-British classification, will require
attention.74-76 In fact, these patients often behave like
patients with AML, are usually resistant to cytoreductive
agents and chemotherapy, and are characterized by pre-
dominant erythropoiesis (>50% of bone marrow cells).
The poor prognosis of these patients is also reflected by
their poor-risk cytogenetics, often in the form of a com-
plex karyotype. If possible, debulking with poly-
chemotherapy (regimens used for AML) or hypomethy-
lating agents should be considered, and in young and fit
patients, intensive post-debulking therapy, preferably in
the form of hematopoietic stem cell transplantation,
(HSCT) is often recommended.77-79
Treatment of anemias: novel agents and concepts 
During the workshop, standard treatments and novel
therapeutic approaches for various forms of anemias were
discussed. With regard to erythropoietin, standard indica-
tions remain renal anemia and anemic patients with MDS
in whom a relative erythropoietin deficiency has been
documented and a response to erythropoietin is seen.80-84
For other similar indications, such as anemia with low
endogenous erythropoietin levels accompanying myelo-
mas, lymphomas or chronic leukemias, treatment with
erythropoiesis-stimulating agents (ESA) may also be use-
ful.85,86 Even in some form of ICUS (elderly ICUS-A
patients) or anemia of chronic disease, the use of erythro-
poietin may be justified.87,88 However, our faculty is of the
opinion that in all these indications, ‘inadequate’ (insuffi-
cient) production of erythropoietin should be documented
before starting erythropoietin therapy. Moreover, we are
of the opinion that erythropoietin therapy is no longer jus-
tified for patients with solid tumors or other malignant
disorders after chemotherapy (in certain malignancies
tumor cells may express erythropoietin receptor) and
should no longer be considered for patients with elevated
endogenous erythropoietin levels (especially levels >500
U/L). However, there are other potential indications for
erythropoietin and other ESA, such as trauma or certain
neurological disorders.89-91 Although beneficial effects of
erythropoietin for these indications have been document-
ed, the mechanisms contributing to these beneficial
effects have not been elucidated so far.
With regard to the type of erythropoietin preparation or
erythropoietin-like ESA, no major differences in responses
have been reported. In fact, several meta-analyses of
patients with MDS and other indications have shown that
short-acting and long-acting erythropoietin-based drugs
all exert very similar effects.92-94 However, erythropoietin
therapy should always be administered with caution,
especially when hemoglobin levels rise. In fact, it has been
described that hemoglobin levels above 12 g/dL can even
be associated with complications and a poor outcome
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Table 3. Updated WHO classification of myelodysplastic syndromes,
2017.
Variant                                                                                Abbreviation
MDS with single lineage dysplasia                                                   MDS-SLD
MDS with ring sideroblasts                                                                 MDS-RS
MDS with ring sideroblasts and single lineage dysplasia      MDS-RS-SLD
MDS with ring sideroblasts and multilineage dysplasia        MDS-RS-MLD
MDS with multilineage dysplasia                                                      MDS-MLD
MDS with excess blasts                                                                       MDS-EB
MDS with isolated del(5q)                                                                         -
MDS unclassifiable                                                                                MDS-U
Provisional entity: refractory cytopenia of childhood                          -
WHO: World Health Organization; MDS: myelodysplastic syndrome.
Table 4. Overview of red cell neoplasms.
Neoplasm                                             Key Features / Criteria
Myelodysplastic syndrome with                Bone marrow cell dysplasia
erythroid predominance                             >50% erythroid cells and 
                                                                         myeloblasts <20%
Pure erythroid leukemia                             Proerythroblasts ≥30% and
                                                                         >80% of all BM cells are erythroid
                                                                         cells; myeloblasts <20%
Polycythemia vera                                         JAK2 V617F or CALRmutations
                                                                         and myeloblasts <20% and
                                                                         WHO criteria for PV fulfilled
WHO: World Health Organization; BM: bone marrow: PV: polycythemia very; JAK2:
janus kinase 2; CALR: calreticulin.
compared to hemoglobin levels below 12 g/dL, especially
in patients with chronic kidney disease.95 The target
hemoglobin level should, therefore, be around 11 g/dL
independently of the ESA applied, underlying disease, or
age. For some indications, the use of additional drugs,
together with erythropoietin/ESA, may be useful. For
example, in patients with chronic kidney disease or chron-
ic inflammation, addition of iron may lead to a more rapid
correction of anemia.96-98 In MDS, the addition of granulo-
cyte or granulocyte-macrophage colony-stimulating factor
may work and increase the rate of responding patients.83,84
In other patients, low erythropoietin synthesis may be
accompanied by other insufficiencies that need to be cor-
rected, such as a lack of vitamin B12, iron deficiency or
folate deficiency.   
There are also other (in part novel) emerging agents that
may be useful in patients with anemias. These drugs
include, among others, hypoxia-inducible factor stabiliz-
ing compounds, prolyl hydroxylase inhibitors, and
activin/GDF11-trapping agents such as sotatercept or lus-
patercept.97-105 The latter may even work in bone marrow
failure syndromes. In addition, GDF11 blockers are able to
counteract anemia in patients with b-thalassemia.42,101
However, in advanced bone marrow neoplasms, such as
MDS, or in aplastic anemia, the effectiveness of broadly
acting growth factors, ESA and other drugs (mentioned
above) is limited. In these patients, the use of disease-
modifying agents, such as demethylating agents and/or
chemotherapy in MDS or immunosuppressive therapy in
aplastic anemia may lead to an improvement or even cor-
rection of the anemia. In low-risk MDS patients with iso-
lated 5q-, lenalidomide therapy usually works well and
often leads to transfusion independence or even to a cyto-
genetic response. In patients with paroxysmal nocturnal
hemoglobinuria the use of complement-targeting drugs
has revolutionized the treatment of anemia. Finally, sever-
al new agents are currently being tested in patients with
hemolytic anemia, thalassemia, or anemia of chronic
inflammation. A detailed description of these agents and
of new treatment approaches is beyond the scope of this
article - we refer the interested reader to the available lit-
erature.
Red cell neoplasms
Red cell neoplasms: classification and criteria
Red cell neoplasms can be classified according to their
etiology (de novo or secondary, i.e. following MDS or a
mutagenic event), WHO criteria and the presence or
absence of certain molecular markers. Erythroid neo-
plasms include PV (JAK2-mutated or wild-type JAK2),
MDS with a prominent erythroid compartment (previous-
ly AML M6) and (pure) erythroid leukemia (Table 4).
Based on the 2017 update of the WHO classification, ery-
throid neoplasms have been reclassified.74,75,106 In the previ-
ous definition provided by  the French-American-British
group and later by the WHO, a blast cell percentage of
≥20% in the non-erythroid compartment together with
erythroid predominance (≥50% of nucleated bone mar-
row cells) was indicative of AML (AML M6). In the 2017
update of the WHO classification, these cases are reclassi-
fied as MDS (usually MDS with excess blasts) unless the
total blast cell percentage (without subtracting erythroid
cells) is ≥20%.74-76 In the case of a total blast cell percentage
of ≥20% and erythroid predominance, the final diagnosis
is AML [AML not otherwise specified (NOS), acute ery-
throid leukemia of erythroid/myeloid type] unless molec-
ular or cytogenetic markers identify another AML sub-
type.74-76 In those with >80% immature erythroid precur-
sors, ≥30% proerythroblasts and a total blast cell percent-
age <20%, the final diagnosis is acute erythroid leukemia
(AML, pure erythroid type). In an updated revision, AML
NOS, acute erythroid leukemia (erythroid/myeloid type)
was replaced by AML NOS (erythroid subtype).106 Overall,
the erythroid leukemias appear to comprise a heteroge-
neous group of malignancies. For example, erythroid
leukemias can occur as primary (de novo) leukemia or as a
secondary form of leukemia, for instance, following MDS
or MPN (Online Supplementary Table S1). In rare cases, even
the blast phase of Philadelphia chromosome-positive
chronic myeloid leukemia may have a clinical and patho-
logical picture indistinguishable from that of ery-
throleukemia (Online Supplementary Figure S2). It is also
important to note that erythroleukemia can develop as an
acute and rapidly progressive disease or a more chronic
form of leukemia. The acute forms of erythroid leukemias
represent a diagnostic challenge and may be overlooked.
Rarely, acute erythroleukemia presents as a large-cell
anaplastic neoplasm mimicking a histiocytic malignancy
or even small-cell carcinoma; such cases can also easily be
overlooked unless appropriate phenotypic studies with
antibodies against glycophorin A/C or CD71 are conduct-
ed (H-PH, unpublished observation). The chronic form of
erythroleukemia must be distinguished from PV and reac-
tive erythrocytosis (polyglobulia), for example, in cases
with an erythropoietin-producing tumor.  
The diagnostic criteria for PV have also changed.
Whereas expression of the JAK2 V617F mutation is still
considered a major criterion of PV the threshold levels of
hemoglobin were changed: in the 2008 WHO definition,
cut-offs were 16.5 g/dL for females and 18.5 g/dL for
males, while in the 2017 revision, hemoglobin cut-offs
were 16.0 g/dL for females and 16.5 g/dL for males.74,75
Although rather specific for MPN and often found in PV
patients, CALRmutations are not yet regarded as diagnos-
tic criteria of MPN/PV. A summary of erythroid neoplasms
is provided in Table 4.
Molecular mechanisms regulating red cell neoplasms
In many instances, the molecular mechanisms underly-
ing red cell expansion in MPN or erythroid leukemias
remain unknown. In the classical MPN, including PV, the
JAK2 point mutation V617F and CALR mutations are con-
sidered to act as major disease drivers. One critical aspect
is that these mutant forms initiate complex networks of
signaling cascades that drive the affected cell and trigger
growth factor independence. A detailed description of
these networks is beyond the scope of this review. Some
of the most important networks are shown in Online
Supplementary Figure S1. The faculty also discussed novel
preclinical models of red cell neoplasms. Based on recent
molecular insights into the etiology of PV and erythroid
leukemias, several mouse models have been established.
In the field of PV/MPN these models are primarily based
on the JAK2 mutation V617F and CALR mutations.107-110
Indeed, mice expressing a mutated and thus hyperactive
Jak2 may develop a MPN-like condition over time.107-110
However, additional factors (mutations or signaling mole-
cules) are required to convert the condition into a full-
P. Valent et al.
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blown malignancy. These additional anomalies are indeed
found in patients with MPN/PV or secondary AML and
are, therefore, of clinical significance.111-116 They include
mutations in TP53 and in various driver genes.112-116 Several
of these changes lead to hyperactive signaling in clinically
relevant pro-oncogenic signaling networks. For example,
molecular changes that lead to an increased production
and accumulation of tyrosine-phosphorylated STAT5 (a
critical JAK2-downstream transcription factor) can trans-
form an indolent MPN-like condition into a highly fatal
disease with major thromboembolism in mice (RM and
PV, unpublished observation).
In contrast to PV and other MPN, very little is known
about the molecular mechanisms underlying the evolu-
tion and progression of erythroid-rich MDS and erythroid
leukemia. In fact, despite a growing list of mutations
associated with erythroid leukemia, their role in the initi-
ation and/or maintenance of the erythroid phenotype
remains largely unknown.115-118 Whereas earlier studies
showed that particular viruses, such as the avian ery-
throblastosis virus and Friend spleen focus-forming virus,
can induce neoplasms resembling erythroid leukemia in
various animal models, no evidence of a viral etiology for
the human disease has been identified so far. All in all, the
faculty concluded that more research is needed to deci-
pher molecular players and targets in these highly fatal
neoplasms.
Therapy of red cell neoplasms 
Despite novel treatment options, early and advanced
erythroid neoplasms are still regarded as incurable malig-
nancies. Most PV patients can be managed quite well
with phlebotomy. If phlebotomy alone is not sufficient
to bring erythrocyte counts under control (target hemat-
ocrit: <45%) or thromboembolic events occur, additional
cytoreductive therapy is recommended. Depending on
age, risk factors, and expected adverse side effects, inter-
feron-α or hydroxyurea can be prescribed. In highly
symptomatic cases, ruxolitinib may be considered. For
patients whose disease transforms into secondary AML,
poly-chemotherapy or, in some cases, hypomethylating
agents, plus HSCT should be considered. The same holds
true for patients with advanced MDS and prominent ery-
thropoiesis (previously AML M6) and cases with full-
blown erythroid leukemia (fulfilling 2017 WHO
criteria).77,78 In these patients, hypomethylating agents (5-
azacytidine or decitabine) or polychemotherapy (AML
regimens) should be considered for debulking prior to
HSCT.
Unfortunately, however, HSCT can only be offered to a
restricted group of young and fit patients. In all patients,
the risk of HSCT-related mortality and morbidity must be
weighed against the potential benefit. The probability of
long-term disease-free survival after HSCT is probably in
the same range as that seen in secondary AML following
MDS. In some of these patients, hypomethylating agents
may exert clinically meaningful anti-neoplastic effects.79
Especially in older patients or those who cannot tolerate
intensive chemotherapy, treatment with hypomethylating
agents is often recommended as first-line therapy.
Hypomethylating agents can also be considered for
patients who are refractory to or relapse after poly-
chemotherapy. When hypomethylating agents fail and the
patient is fit, polychemotherapy or experimental drugs
should be considered. Hydroxyurea is the palliative drug
of choice in multi-resistant patients and those who are old
and refuse intensive or experimental therapy. 
Concluding remarks
Red cell production, survival and turnover in health and
disease, and mechanisms regulating these processes, have
attracted the attention of physicians and scientists in the
past five decades and many different mechanisms and
molecules involved in the regulation of red cell production
and survival have been discovered. In addition, a number
of molecular and immunological markers and targets have
been identified in red cells and their progenitors. Several
of these novel antigens may serve as diagnostic markers or
as therapeutic targets. Resulting new diagnostic strategies
and novel treatment concepts should advance the field
and lead to more precise diagnosis, better therapies and
improved prognosis in reactive and clonal erythroid disor-
ders.
Acknowledgments 
We would like to thank Heidi A. Neubauer, Julia Neusiedler-
Nicolas, Sophia-Marie Rammler and Emir Hadzijusufovic for
their excellent technical assistance. This study was supported by
the Austrian Science Fonds, SFB grants F4701-B20, F4704-
B20, F4705-B20 and F4706-B20. 
Normal and pathological erythropoiesis
haematologica | 2018; 103(10) 1601
References
1. Palis J. Primitive and definitive erythro-
poiesis in mammals. Front Physiol. 2014;5:3.
2. Hattangadi SM, Wong P, Zhang L, Flygare J,
Lodish HF. From stem cell to red cell: regula-
tion of erythropoiesis at multiple levels by
multiple proteins, RNAs, and chromatin
modifications. Blood. 2011;118(24):6258-
6268.
3. Kuhrt D, Wojchowski DM. Emerging EPO
and EPO receptor regulators and signal
transducers. Blood. 2015;125(23):3536-3541.
4. Liang R, Ghaffari S. Advances in under-
standing the mechanisms of erythropoiesis
in homeostasis and disease. Br J Haematol.
2016;174(5):661-673.
5. Oburoglu L, Romano M, Taylor N, Kinet S.
Metabolic regulation of hematopoietic stem
cell commitment and erythroid differentia-
tion. Curr Opin Hematol. 2016;23(3):198-
205.
6. Carmel R. Anemia and aging: an overview
of clinical, diagnostic and biological issues.
Blood Rev. 2001;15(1):9-18.
7. Steensma DP, Tefferi A. Anemia in the elder-
ly: how should we define it, when does it
matter, and what can be done? Mayo Clin
Proc. 2007;82(8):958-966.
8. Halawi R, Moukhadder H, Taher A. Anemia
in the elderly: a consequence of aging?
Expert Rev Hematol. 2017;10(4):327-335.
9. Stauder R, Valent P, Theurl I. Anemia at
older age: etiologies, clinical implications
and management. Blood. 2018;131(5):505-
514.
10. Guidi GC, Lechi Santonastaso C.
Advancements in anemias related to chronic
conditions. Clin Chem Lab Med. 2010;48(9):
1217-1226.
11. Valent P. Low blood counts: immune medi-
ated, idiopathic, or myelodysplasia.
Hematology Am Soc Hematol Educ
Program. 2012;2012:485-491.
12. Guillaud C, Loustau V, Michel M. Hemolytic
anemia in adults: main causes and diagnostic
procedures. Expert Rev Hematol. 2012;5(2):
229-241.
13. Camaschella C, Nai A. Ineffective erythro-
poiesis and regulation of iron status in iron
loading anaemias. Br J Haematol. 2016;172
(4):512-523.
14. Shimamura A. Aplastic anemia and clonal
evolution: germ line and somatic genetics.
Hematology Am Soc Hematol Educ
Program. 2016;2016(1):74-82.
15. Hasserjian RP, Howard J, Wood A, Henry K,
Bain B. Acute erythremic myelosis (true ery-
throleukaemia): a variant of AML FAB-M6. J
Clin Pathol. 2001;54(3):205-209.
16. Prchal JT. Polycythemia vera and other pri-
mary polycythemias. Curr Opin Hematol.
2005;12(2):112-116.
17. Wang SA, Hasserjian RP. Erythroid prolifera-
tions in myeloid neoplasms. Hum Pathol.
2012;43(2):153-164.
18. Wang W, Wang SA, Medeiros LJ, Khoury JD.
Pure erythroid leukemia. Am J Hematol.
2017;92(3):292-296.
19. Wu H, Liu X, Jaenisch R, Lodish HF.
Generation of committed erythroid BFU-E
and CFU-E progenitors does not require ery-
thropoietin or the erythropoietin receptor.
Cell. 1995;83(1):59-67.
20. Cantor AB, Orkin SH. Transcriptional regu-
lation of erythropoiesis: an affair involving
multiple partners. Oncogene. 2002;21(21):
3368-3376.
21. Donovan A, Andrews NC. The molecular
regulation of iron metabolism. Hematol J.
2004;5(5):373-380.
22. Kim SI, Bresnick EH. Transcriptional control
of erythropoiesis: emerging mechanisms
and principles. Oncogene. 2007;26(47):6777-
6794.
23. Semenza GL. Regulation of oxygen home-
ostasis by hypoxia-inducible factor 1.
Physiology (Bethesda). 2009;24:97-106.
24. Haase VH. Regulation of erythropoiesis by
hypoxia-inducible factors. Blood Rev. 2013;
27(1):41-53.
25. Hermine O, Arlet JB, Ribeil JA, Guillerm F,
Vandekerkhove J, Courtois G. HSP70, an
erythropoiesis regulator that determines the
fate of erythroblasts between death and dif-
ferentiation. Transfus Clin Biol. 2013;20(2):
144-147.
26. Kautz L, Nemeth E. Molecular liaisons
between erythropoiesis and iron metabo-
lism. Blood. 2014;124(4):479-482.
27. Simon MC, Pevny L, Wiles MV, Keller G,
Costantini F, Orkin SH. Rescue of erythroid
development in gene targeted GATA-1-
mouse embryonic stem cells. Nat Genet.
1992;1(2):92-98.
28. Simon MC. Transcription factor GATA-1
and erythroid development.  Proc Soc Exp
Biol Med. 1993;202(2):115-121.
29. Kaneko H, Shimizu R, Yamamoto M. GATA
factor switching during erythroid differenti-
ation. Curr Opin Hematol. 2010;17(3):163-
168.
30. Ribeil JA, Zermati Y, Vandekerckhove J, et
al. Hsp70 regulates erythropoiesis by pre-
venting caspase-3-mediated cleavage of
GATA-1. Nature. 2007;445(7123):102-105.
31. Arlet JB, Ribeil JA, Guillem F, et al. HSP70
sequestration by free b-globin promotes
ineffective erythropoiesis in b-thalassaemia.
Nature. 2014;514(7521):242-246
32. Smith TG, Robbins PA, Ratcliffe PJ. The
human side of hypoxia-inducible factor. Br J
Haematol. 2008;141(3):325-334.
33. Muckenthaler MU, Rivella S, Hentze MW,
Galy B. A red carpet for iron metabolism.
Cell. 2017;168(3):344-361.
34. Kautz L, Jung G, Valore EV, Rivella S,
Nemeth E, Ganz T. Identification of erythro-
ferrone as an erythroid regulator of iron
metabolism. Nat Genet. 2014;46(7):678-684.
35. Coulon S, Dussiot M, Grapton D, et al.
Polymeric IgA1 controls erythroblast prolif-
eration and accelerates erythropoiesis recov-
ery in anemia. Nat Med. 2011;17(11):1456-
1465.
36. Frisan E, Vandekerckhove J, de Thonel A, et
al. Defective nuclear localization of Hsp70 is
associated with dyserythropoiesis and
GATA-1 cleavage in myelodysplastic syn-
dromes. Blood. 2012;119(6):1532-1542.
37. Gastou M, Rio S, Dussiot M, et al. The
severe phenotype of Diamond-Blackfan
anemia is modulated by heat shock protein
70. Blood Adv. 2017;1(22):1959-1976.
38. Maguer-Satta V, Bartholin L, Jeanpierre S, et
al. Regulation of human erythropoiesis by
activin A, BMP2, and BMP4, members of the
TGFbeta family. Exp Cell Res. 2003;282
(2):110-120.
39. Socolovsky M, Murrell M, Liu Y, Pop R,
Porpiglia E, Levchenko A. Negative autoreg-
ulation by FAS mediates robust fetal ery-
thropoiesis. PLoS Biol. 2007;5(10):e252.
40. Liu Y, Pop R, Sadegh C, Brugnara C, Haase
VH, Socolovsky M. Suppression of Fas-FasL
coexpression by erythropoietin mediates
erythroblast expansion during the erythro-
poietic stress response in vivo. Blood.
2006;108(1):123-133.
41. Wang Q, Huang Z, Xue H, et al. MicroRNA
miR-24 inhibits erythropoiesis by targeting
activin type I receptor ALK4. Blood.
2008;111(2):588-595.
42. Dussiot M, Maciel TT, Fricot A, et al. An
activin receptor IIA ligand trap corrects inef-
fective erythropoiesis in b-thalassemia. Nat
Med. 2014;20(4):398-407.
43. Koulnis M, Porpiglia E, Hidalgo D,
Socolovsky M. Erythropoiesis: from molec-
ular pathways to system properties. Adv
Exp Med Biol. 2014;844:37-58.
44. Vlahakos DV, Marathias KP, Madias NE.
The role of the renin-angiotensin system in
the regulation of erythropoiesis. Am J
Kidney Dis. 2010;56(3):558-565.
45. Kim YC, Mungunsukh O, Day RM.
Erythropoietin regulation by angiotensin II.
Vitam Horm. 2017;105:57-77.
46. Lee PL, Beutler E. Regulation of hepcidin and
iron-overload disease. Annu Rev Pathol.
2009;4:489-515.
47. Silva B, Faustino P. An overview of molecu-
lar basis of iron metabolism regulation and
the associated pathologies. Biochim Biophys
Acta. 2015;1852(7):1347-1359.
48. Wang CY, Babitt JL. Hepcidin regulation in
the anemia of inflammation. Curr Opin
Hematol. 2016;23(3):189-197.
49. Uras IZ, Scheicher RM, Kollmann K, et al.
Cdk6 contributes to cytoskeletal stability in
erythroid cells. Haematologica. 2017;102
(6):995-1005.
50. Valent P, Horny HP, Bennett JM, et al.
Definitions and standards in the diagnosis
and treatment of the myelodysplastic syn-
dromes: consensus statements and report
from a working conference. Leuk Res.
2007;31(6):727-736.
51. Steensma DP, Bejar R, Jaiswal S, et al. Clonal
hematopoiesis of indeterminate potential
and its distinction from myelodysplastic
syndromes. Blood. 2015;126(1):9-16.
52. Valent P, Orazi A, Steensma DP, et al.
Proposed minimal diagnostic criteria for
myelodysplastic syndromes (MDS) and
potential pre-MDS conditions. Oncotarget
2017:8(43):73483-73500.
53. Malcovati L, Della Porta MG, Lunghi M, et
al. Flow cytometry evaluation of erythroid
and myeloid dysplasia in patients with
myelodysplastic syndrome. Leukemia.
2005; 19(5):776-783.
54. Della Porta MG, Malcovati L, Invernizzi R,
et al. Flow cytometry evaluation of ery-
throid dysplasia in patients with myelodys-
plastic syndrome. Leukemia.
2006;20(4):549-555.
55. Xu F, Wu L, He Q, Zhang Z, Chang C, Li X.
Immunophenotypic analysis of erythroid
dysplasia and its diagnostic application in
myelodysplastic syndromes. Intern Med J.
2012;42(4):401-411.
56. Eidenschink Brodersen L, Menssen AJ, et al.
Assessment of erythroid dysplasia by "dif-
ference from normal" in routine clinical flow
cytometry workup. Cytometry B Clin
Cytom. 2015;88(2):125-135.
57. Bühring HJ, Müller T, Herbst R, et al. The
adhesion molecule E-cadherin and a surface
antigen recognized by the antibody 9C4 are
selectively expressed on erythroid cells of
defined maturational stages. Leukemia.
1996;10(1):106-116.
58. Bauer K, Machherndl-Spandl S, Suessner S,
et al. Identification of CAR as a novel medi-
ator of erythroid differentiation and migra-
tion that is specifically downregulated in
erythropoietic progenitor cells in patients
with MDS. Blood. 2014;124(21):1570.
59. Chasis JA, Mohandas N. Erythroblastic
islands: niches for erythropoiesis. Blood.
2008;112(3):470-478.
60. Buesche G, Teoman H, Giagounidis A, et al.
Impaired formation of erythroblastic islands
is associated with erythroid failure and poor
prognosis in a significant proportion of
patients with myelodysplastic syndromes.
Haematologica. 2016;101(5):e177-e181. 
61. Moriyama Y, Sato M, Kinoshita Y. Studies
on hematopoietic stem cells: XI. Lack of ery-
throid burst-forming units (BFU-E) in
patients with aplastic anemia. Am J
Hematol. 1979;6(1):11-16.
62. Amato D, Khan NR. Erythroid burst forma-
tion in cultures of bone marrow and periph-
eral blood from patients with refractory ane-
mia. Acta Haematol. 1983;70(1):1-10.
63. Geissler K, Hinterberger W, Jäger U, et al.
Deficiency of pluripotent hemopoietic pro-
genitor cells in myelodysplastic syndromes.
Blut. 1988;57(1):45-49.
64. Manor D, Rachmilewitz EA, Fibach E.
Improved method for diagnosis of poly-
cythemia vera based on flow cytometric
analysis of autonomous growth of erythroid
precursors in liquid culture. Am J Hematol.
1997;54(1):47-52.
65. Geissler K, Ohler L, Födinger M, et al.
Interleukin-10 inhibits erythropoietin-inde-
pendent growth of erythroid bursts in
patients with polycythemia vera. Blood.
1998;92(6):1967-1972.
66. Sifakis S, Pharmakides G. Anemia in preg-
nancy. Ann N Y Acad Sci. 2000;900:125-136.
67. Milman N. Postpartum anemia I: definition,
prevalence, causes, and consequences. Ann
Hematol. 2011;90(11):1247-1253.
68. Zakai NA, Katz R, Hirsch C, Shlipak MG,
Chaves PH, Newman AB, Cushman M. A
prospective study of anemia status, hemo-
globin concentration, and mortality in an
elderly cohort: the Cardiovascular Health
Study. Arch Intern Med. 2005;165(19):2214-
2220.
69. Chaves PH, Xue QL, Guralnik JM, Ferrucci
L, Volpato S, Fried LP. What constitutes nor-
mal hemoglobin concentration in communi-
ty-dwelling disabled older women? J Am
Geriatr Soc. 2004;52(11):1811-1816.
70. Steensma DP, Tefferi A. Anemia in the elder-
ly: how should we define it, when does it
matter, and what can be done? Mayo Clin
P. Valent et al.
1602 haematologica | 2018; 103(10)
Proc. 2007;82(8):958-966.
71. Valent P, Horny HP. Minimal diagnostic cri-
teria for myelodysplastic syndromes and
separation from ICUS and IDUS: update and
open questions. Eur J Clin Invest. 2009;39
(7):548-553.
72. Valent P. Anemia of the elderly (AOE): does it
exist and does it matter in clinical practice?
Eur J Clin Invest. 2008;38(10):782-783.
73. Bachman E, Travison TG, Basaria S, et al.
Testosterone induces erythrocytosis via
increased erythropoietin and suppressed
hepcidin: evidence for a new erythropoi-
etin/hemoglobin set point. J Gerontol A Biol
Sci Med Sci. 2014;69(6):725-735.
74. Arber DA, Hasserjian RP. Reclassifying
myelodysplastic syndromes: what's where
in the new WHO and why. Hematology Am
Soc Hematol Educ Program. 2015;2015:294-
298.
75. Arber DA, Orazi A, Hasserjian R, et al. The
2016 revision to the World Health
Organization classification of myeloid neo-
plasms and acute leukemia. Blood.
2016;127(20):2391-405.
76. Strupp C, Nachtkamp K, Hildebrandt B, et al.
New proposals of the WHO working group
(2016) for the diagnosis of myelodysplastic
syndromes (MDS): characteristics of refined
MDS types. Leuk Res. 2017;57:78-84.
77. Fouillard L, Labopin M, Gorin NC, et al;
Acute Leukemia Working Party of the
EBMT. Hematopoietic stem cell transplanta-
tion for de novo erythroleukemia: a study of
the European Group for Blood and Marrow
Transplantation (EBMT). Blood. 2002;
100(9):3135-3140.
78. Ishiyama K, Yamaguchi T, Eto T, et al. Acute
megakaryoblastic leukemia, unlike acute
erythroid leukemia, predicts an unfavorable
outcome after allogeneic HSCT. Leuk Res.
2016;47:47-53.
79. Almeida AM, Prebet T, Itzykson R, et al.
Clinical outcomes of 217 patients with acute
erythroleukemia according to treatment
type and line: a retrospective multinational
study. Int J Mol Sci. 2017;18(4).
80. Schmid H, Schiffl H. Erythropoiesis stimu-
lating agents and anaemia of end-stage renal
disease. Cardiovasc Hematol Agents Med
Chem. 2010;8(3):164-172.
81. Ramanath V, Gupta D, Jain J, Chaudhary K,
Nistala R. Anemia and chronic kidney dis-
ease: making sense of the recent trials. Rev
Recent Clin Trials. 2012;7(3):187-196.
82. Mimura I, Tanaka T, Nangaku M. How the
target hemoglobin of renal anemia should
be. Nephron. 2015;131(3):202-209.
83. Hellström-Lindberg E, Gulbrandsen N,
Lindberg G, et al; Scandinavian MDS Group.
A validated decision model for treating the
anaemia of myelodysplastic syndromes
with erythropoietin + granulocyte colony-
stimulating factor: significant effects on
quality of life. Br J Haematol. 2003;120
(6):1037-1046.
84. Hellström-Lindberg E, van de Loosdrecht A.
Erythropoiesis stimulating agents and other
growth factors in low-risk MDS. Best Pract
Res Clin Haematol. 2013;26(4):401-410.
85. Ludwig H, Fritz E, Kotzmann H, Höcker P,
Gisslinger H, Barnas U. Erythropoietin treat-
ment of anemia associated with multiple
myeloma. N Engl J Med. 1990;322(24):1693-
1699.
86. San Miguel JF, García-Sanz R. Recombinant
human erythropoietin in the anaemia of
multiple myeloma and non-Hodgkin's lym-
phoma. Med Oncol. 1998;15:S29-S34.
87. Agnihotri P, Telfer M, Butt Z, et al. Chronic
anemia and fatigue in elderly patients:
results of a randomized, double-blind, place-
bo-controlled, crossover exploratory study
with epoetin alfa. J Am Geriatr Soc.
2007;55(10):1557-1565.
88. Agarwal N, Prchal JT. Erythropoietic agents
and the elderly. Semin Hematol. 2008;45(4):
267-275.
89. Hasselblatt M, Ehrenreich H, Sirén AL. The
brain erythropoietin system and its potential
for therapeutic exploitation in brain disease. J
Neurosurg Anesthesiol. 2006;18(2):132-138.
90. Westenbrink BD, Voors AA, Ruifrok WP, van
Gilst WH, van Veldhuisen DJ. Therapeutic
potential of erythropoietin in cardiovascular
disease: erythropoiesis and beyond. Curr
Heart Fail Rep. 2007;4(3):127-133.
91. Brines M. The therapeutic potential of ery-
thropoiesis-stimulating agents for tissue pro-
tection: a tale of two receptors. Blood Purif.
2010;29(2):86-92.
92. Wilhelm-Leen ER, Winkelmayer WC.
Mortality risk of darbepoetin alfa versus
epoetin alfa in patients with CKD: systemat-
ic review and meta-analysis. Am J Kidney
Dis. 2015;66(1):69-74.
93. Pérez-Ruixo JJ, Cucala-Ramos M, García-
Gonzalo E, Del Val Romero B, Valveny N.
Between subjects variability in haemoglobin
and dose are not associated with the ery-
thropoiesis-stimulating agent used to treat
anaemia in dialysis: a meta-analysis. Br J
Clin Pharmacol. 2013;75(1):15-25.
94. Park S, Fenaux P, Greenberg P, et al. Efficacy
and safety of darbepoetin alpha in patients
with myelodysplastic syndromes: a system-
atic review and meta-analysis. Br J
Haematol. 2016;174(5):730-747.
95. Pfeffer MA, Burdmann EA, Chen CY, et al;
TREAT Investigators. A trial of darbepoetin
alfa in type 2 diabetes and chronic kidney dis-
ease. N Engl J Med. 2009;361(21):2019-2032.
96. Shirazian S, Grant C, Miller I, Fishbane S.
How can erythropoeitin-stimulating agent
use be reduced in chronic dialysis patients?:
The use of iron supplementation to reduce
ESA dosing in hemodialysis. Semin Dial.
2013;26(5):534-536.
97. Del Vecchio L, Locatelli F. New treatment
approaches in chronic kidney disease-associ-
ated anaemia. Expert Opin Biol Ther.
2014;14(5):687-696.
98. Bonomini M, Del Vecchio L, Sirolli V,
Locatelli F. New treatment approaches for
the anemia of CKD. Am J Kidney Dis.
2016;67(1):133-142.
99. Macdougall IC, Ashenden M. Current and
upcoming erythropoiesis-stimulating
agents, iron products, and other novel ane-
mia medications. Adv Chronic Kidney Dis.
2009;16(2):117-130.
100.Raje N, Vallet S. Sotatercept, a soluble activin
receptor type 2A IgG-Fc fusion protein for the
treatment of anemia and bone loss. Curr
Opin Mol Ther. 2010;12(5):586-597
101.Arlet JB, Dussiot M, Moura IC, Hermine O,
Courtois G. Novel players in b-thalassemia
dyserythropoiesis and new therapeutic
strategies. Curr Opin Hematol. 2016;23
(3):181-188.
102. Jelkmann W. The ESA scenario gets com-
plex: from biosimilar epoetins to activin
traps. Nephrol Dial Transplant. 2015;30(4):
553-559.
103.Liu J, Sun B, Yin H, Liu S. Hepcidin: A prom-
ising therapeutic target for iron disorders: a
systematic review. Medicine (Baltimore).
2016;95(14):e3150.
104.Sugahara M, Tanaka T, Nangaku M. Prolyl
hydroxylase domain inhibitors as a novel
therapeutic approach against anemia in
chronic kidney disease. Kidney Int.
2017;92(2):306-312.
105.Almeida A, Fenaux P, List AF, Raza A,
Platzbecker U, Santini V. Recent advances in
the treatment of lower-risk non-del(5q)
myelodysplastic syndromes (MDS). Leuk
Res. 2017;52:50-57
106.Arber DA. Revisiting erythroleukemia. Curr
Opin Hematol. 2017;24(2):146-151.
107.Lacout C, Pisani DF, Tulliez M, Gachelin FM,
Vainchenker W, Villeval JL. JAK2V617F
expression in murine hematopoietic cells
leads to MPD mimicking human PV with
secondary myelofibrosis. Blood. 2006;108
(5):1652-1660.
108.Akada H, Yan D, Zou H, Fiering S,
Hutchison RE, Mohi MG. Conditional
expression of heterozygous or homozygous
Jak2V617F from its endogenous promoter
induces a polycythemia vera-like disease.
Blood. 2010;115(17):3589-357.
109.Marty C, Pecquet C, Nivarthi H, et al.
Calreticulin mutants in mice induce an MPL-
dependent thrombocytosis with frequent
progression to myelofibrosis. Blood.
2016;127(10):1317-1324.
110.Shide K, Kameda T, Yamaji T, et al.
Calreticulin mutant mice develop essential
thrombocythemia that is ameliorated by the
JAK inhibitor ruxolitinib. Leukemia.
2017;31(5):1136-1144.
111.Rumi E, Harutyunyan A, Elena C, et al.
Identification of genomic aberrations associ-
ated with disease transformation by means
of high-resolution SNP array analysis in
patients with myeloproliferative neoplasm.
Am J Hematol. 2011;86(12):974-979.
112.Cerquozzi S, Tefferi A. Blast transformation
and fibrotic progression in polycythemia
vera and essential thrombocythemia: a liter-
ature review of incidence and risk factors.
Blood Cancer J. 2015;5:e366.
113.Alvarez-Larrán A, Senín A, Fernández-
Rodríguez C, et al. Impact of genotype on
leukaemic transformation in polycythaemia
vera and essential thrombocythaemia. Br J
Haematol. 2017;178(5):764-771.
114.Hidalgo López JE, Carballo-Zarate A, et al.
Bone marrow findings in blast phase of
polycythemia vera. Ann Hematol. 2018;97
(3):425-434.
115.Grossmann V, Bacher U, Haferlach C, et al.
Acute erythroid leukemia (AEL) can be sepa-
rated into distinct prognostic subsets based
on cytogenetic and molecular genetic charac-
teristics. Leukemia. 2013;27(9):1940-1943.
116.Cervera N, Carbuccia N, Garnier S, et al.
Molecular characterization of acute ery-
throid leukemia (M6-AML) using targeted
next-generation sequencing.  Leukemia.
2016;30(4):966-970.
117.Ping N, Sun A, Song Y, et al. Exome sequenc-
ing identifies highly recurrent somatic
GATA2 and CEBPA mutations in acute ery-
throid leukemia. Leukemia. 2017;31(1):195-
202.
118.Montalban-Bravo G, Benton CB, Wang SA,
et al. More than 1 TP53 abnormality is a
dominant characteristic of pure erythroid
leukemia. Blood. 2017;129(18):2584-2587.
Normal and pathological erythropoiesis
haematologica | 2018; 103(10) 1603
